DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice

Journal of Molecular Endocrinology

Volumn 49, Issue 2, 2012, Pages 125-135

  Shimizu, Shinobu ^a   Hosooka, Tetsuya ^a   Matsuda, Tomokazu ^a   Asahara, Shun ichiro ^a   Koyanagi Kimura, Maki ^a   Kanno, Ayumi ^a   Bartolome, Alberto ^b   Etoh, Hiroaki ^a   Fuchita, Megumi ^a   Teruyama, Kyoko ^a   Takahashi, Hiroaki ^a   Inoue, Hiroyuki ^a   Mieda, Yusuke ^a   Hashimoto, Naoko ^a   Seino, Susumu ^a,c   Kido, Yoshiaki ^a  

^a KOBE UNIVERSITY   (Japan)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CCAAT ENHANCER BINDING PROTEIN BETA; EXENDIN 4; GLUCAGON; HOMEODOMAIN PROTEIN; INSULIN; MESSENGER RNA; PROTEASOME; SOMATOMEDIN C; VILDAGLIPTIN; CASPASE 3; GLUCOSE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2ALPHA; PROTEIN KINASE B;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL PROLIFERATION; CELL PROTECTION; CELL SPECIFICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GLUCAGON BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; DISEASE COURSE; DRUG EFFECT; FOOD INTAKE; GENE EXPRESSION; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; INNER CELL MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

ADAMANTANE; ANIMALS; BLOOD GLUCOSE; CCAAT-ENHANCER-BINDING PROTEIN-BETA; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; ENDOPLASMIC RETICULUM STRESS; GENE EXPRESSION REGULATION; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HYPERGLYCEMIA; INSULIN; INSULIN-SECRETING CELLS; LEUPEPTINS; MICE; MICE, TRANSGENIC; NITRILES; PEPTIDES; PYRROLIDINES; VENOMS;

EID: 84866398736     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-12-0039     Document Type: Article

References (36)

1. Ahren B, Foley JE, Ferrannini E, Matthews DR, Zinman B, Dejager S & Fonseca VA 2010 Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Diabetes Care 33 730-732. (doi:10.2337/dc09-1867)
2. Balas B, Baig MR, Watson C, Dunning BE, Ligueros-Saylan M, Wang Y, He YL, Darland C, Holst JJ, Deacon CF et al. 2007 The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. Journal of Clinical Endocrinology and Metabolism 92 1249-1255. (doi:10.1210/jc.2006-1882)
3. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA & Butler PC 2003 b-Cell deficit and increased b cell apoptosis in humans with type 2 diabetes. Diabetes 52 102-110. (doi:10.2337/diabetes.52. 1.102)
4. Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH et al. 2011 A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing b cell replication and neogenesis. Diabetes Research and Clinical Practice 91 72-79. (doi:10.1016/j.diabres.2010.10.012)
5. Cunha DA, Ladriere L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, Marchetti P, Eizirik DL & Cnop M 2009 Glucagon-like peptide-1 agonists protect pancreatic b cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 58 2851-2862. (doi:10.2337/db09-0685)
6. Drucker DJ & Nauck MA 2006 The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368 1696-1705. (doi:10.1016/S0140-6736(06)69705-5)
7. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Subramanian K, Hughes TE & Burkey BF 2011 The DPP-4 inhibitor vildagliptin increases pancreatic b-cell mass in neonatal rats. European Journal of Pharmacology 650 703-707. (doi:10.1016/j.ejphar.2010.10.062)
8. Harding HP & Ron D 2002 Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes 51 (Suppl 3) S455-S461. (doi:10.2337/diabetes.51.2007.S455)
9. Hashimoto N, Kido Y, Uchida T, Matsuda T, Suzuki K, Inoue H, Matsumoto M, Ogawa W, Maeda S, Fujihara H et al. 2005 PKClambda regulates glucose-induced insulin secretion through modulation of gene expression in pancreatic b cells. Journal of Clinical Investigation 115 138-145. (doi:10.1172/JCI200522232)
10. Hashimoto N, Kido Y, Uchida T, Asahara S, Shigeyama Y, Matsuda T, Takeda A, Tsuchihashi D, Nishizawa A, OgawaWet al. 2006 Ablation of PDK1 in pancreatic b cells induces diabetes as a result of loss of bcell mass. Nature Genetics 38 589-593. (doi:10.1038/ng1774)
11. Holst JJ & Deacon CF 2004 Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Current Opinion in Pharmacology 4 589-596. (doi:10.1016/j.coph. 2004.08.005)
12. Holst JJ & Gromada J 2004 Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology. Endocrinology and Metabolism 287 E199-E206. (doi:10.1152/ajpendo.00545.2003)
13. Jhala US, Canettieri G, Screaton RA, Kulkarni RN, Krajewski S, Reed J, Walker J, Lin X, White M & Montminy M 2003 cAMP promotes pancreatic b cell survival via CREB-mediated induction of IRS2. Genes and Development 17 1575-1580. (doi:10.1101/gad.1097103)
14. Kido Y, Burks DJ, Withers D, Bruning JC, Kahn CR, White MF & Accili D 2000 Tissue-specific insulin resistance in mice with mutations in the insulin receptor, IRS-1, and IRS-2. Journal of Clinical Investigation 105 199-205. (doi:10.1172/JCI7917)
15. Kitamura T, Nakae J, Kitamura Y, Kido Y, Biggs WH, Wright CV, White MF, Arden KC & Accili D 2002 The forkhead transcription factor Foxo1 links insulin signaling to Pdx1 regulation of pancreatic b cell growth. Journal of Clinical Investigation 110 1839-1847.
16. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, Tsubamoto Y, Komeda K, Nakano R, Miki H et al. 2000 Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory b cell hyperplasia. Diabetes 49 1880-1889. (doi:10.2337/diabetes.49.11.1880)
17. Kulkarni RN, Bruning JC, Winnay JN, Postic C, Magnuson MA & Kahn CR 1999 Tissue-specific knockout of the insulin receptor in pancreatic b cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 96 329-339. (doi:10.1016/S0092-8674(00)80546-2)
18. Li Y, Hansotia T, Yusta B, Ris F, Halban PA & Drucker DJ 2003 Glucagon-like peptide-1 receptor signaling modulates b cell apoptosis. Journal of Biological Chemistry 278 471-478. (doi:10.1074/jbc.M209423200)
19. Matsuda T, Kido Y, Asahara S, Kaisho T, Tanaka T, Hashimoto N, Shigeyama Y, Takeda A, Inoue T, Shibutani Y et al. 2010 Ablation of C/EBPb alleviates ER stress and pancreatic b cell failure through the GRP78 chaperone in mice. Journal of Clinical Investigation 120 115-126. (doi:10.1172/JCI39721)
20. McKinnon CM & Docherty K 2001 Pancreatic duodenal homeobox-1, PDX-1, a major regulator of b cell identity and function. Diabetologia 44 1203-1214. (doi:10.1007/s001250100628)
21. Mu J, Petrov A, Eiermann GJ, Woods J, Zhou YP, Li Z, Zycband E, Feng Y, Zhu L, Roy RS et al. 2009 Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes. European Journal of Pharmacology 623 148-154. (doi:10.1016/j.ejphar.2009.09.027)
22. Park S, Dong X, Fisher TL, Dunn S, Omer AK, Weir G & White MF 2006 Exendin-4 uses Irs2 signaling to mediate pancreatic b cell growth and function. Journal of Biological Chemistry 281 1159-1168. (doi:10.1074/jbc.M508307200)
23. Rhodes CJ 2005 Type 2 diabetes-a matter of b cell life and death? Science 307 380-384. (doi:10.1126/science.1104345)
24. Stoffers DA 2004 The development of b-cell mass: recent progress and potential role of GLP-1. Hormone and Metabolic Research 36 811-821. (doi:10.1055/s-2004-826168)
25. Ueki K, Okada T, Hu J, Liew CW, Assmann A, Dahlgren GM, Peters JL, Shackman JG, Zhang M, Artner I et al. 2006 Total insulin and IGF-I resistance in pancreatic b cells causes overt diabetes. Nature Genetics 38 583-588. (doi:10.1038/ng1787)
26. UK Prospective Diabetes Study (UKPDS) Group 1998a Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).
27. UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 854-865. (doi:10.1016/S0140-6736(98)07037-8)
28. UK Prospective Diabetes Study (UKPDS) Group 1998b Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
29. UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 837-853. (doi:10.1016/S0140-6736(98)07019-6)
30. Wajchenberg BL 2007 b-Cell failure in diabetes and preservation by clinical treatment. Endocrine Reviews 28 187-218. (doi:10.1210/10. 1210/er.2006-0038)
31. Wang Q & Brubaker PL 2002 Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia 45 1263-1273. (doi:10.1007/s00125-002-0828-3)
32. Weyer C, Bogardus C, Mott DM & Pratley RE 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. Journal of Clinical Investigation 104 787-794. (doi:10.1172/JCI7231)
33. Widenmaier SB, Kim SJ, Yang GK, De Los Reyes T, Nian C, Asadi A, Seino Y, Kieffer TJ, Kwok YN & McIntosh CHS 2010 A GIP receptor agonist exhibits B-cell anti-apoptotic actions in rat models of diabetes resulting in improved B-cell function and glycemic control. PLoS ONE 5 e9590. (doi:10.1371/journal.pone. 0009590)
34. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, Zhang Y, Bernal D, Pons S, Shulman GI et al. 1998 Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391 900-904. (doi:10.1038/36116)
35. Xu G, Stoffers DA, Habener JF & Bonner-Weir S 1999 Exendin-4 stimulates both b cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 2270-2276. (doi:10.2337/diabetes.48. 12.2270)
36. Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, Pipeleers D, Ling Z & Drucker DJ 2006 GLP-1 receptor activation improves b cell function and survival following induction of endoplasmic reticulum stress. Cell Metabolism 4 391-406. (doi:10.1016/j.cmet.2006.10.001)